top of page

Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines

Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale production in global markets.

Read the article at:

bottom of page